Ameriprise’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-22,118
| Closed | -$394K | – | 4084 |
|
|
2025
Q1 | $394K | Sell |
22,118
-765
| -3% | -$17.4K | ﹤0.01% | 3583 |
|
|
2024
Q4 | $682K | Buy |
22,883
+10,007
| +78% | +$212K | ﹤0.01% | 3407 |
|
|
2024
Q3 | $201K | Sell |
12,876
-345
| -3% | -$6.26K | ﹤0.01% | 3752 |
|
|
2024
Q2 | $226K | Sell |
13,221
-4,872
| -27% | -$85.7K | ﹤0.01% | 3668 |
|
|
2024
Q1 | $283K | Buy |
18,093
+6,808
| +60% | +$100K | ﹤0.01% | 3604 |
|
|
2023
Q4 | $168K | Buy |
+11,285
| New | +$151K | ﹤0.01% | 3743 |
|
|
2023
Q3 | – | Sell |
-8,196
| Closed | -$340K | – | 3942 |
|
|
2023
Q2 | $340K | Sell |
8,196
-1,134
| -12% | -$70.4K | ﹤0.01% | 3576 |
|
|
2023
Q1 | $561K | Sell |
9,330
-1,218
| -12% | -$97.3K | ﹤0.01% | 3388 |
|
|
2022
Q4 | $774K | Buy |
10,548
+3,278
| +45% | +$247K | ﹤0.01% | 3243 |
|
|
2022
Q3 | $553K | Sell |
7,270
-3,332
| -31% | -$260K | ﹤0.01% | 3353 |
|
|
2022
Q2 | $736K | Sell |
10,602
-1,425
| -12% | -$107K | ﹤0.01% | 3241 |
|
|
2022
Q1 | $979K | Sell |
12,027
-73,802
| -86% | -$5.44M | ﹤0.01% | 3226 |
|
|
2021
Q4 | $6.41M | Buy |
85,829
+72,842
| +561% | +$7.31M | ﹤0.01% | 2297 |
|
|
2021
Q3 | $1.51M | Sell |
12,987
-3,624
| -22% | -$548K | ﹤0.01% | 2980 |
|
|
2021
Q2 | $3.69M | Buy |
16,611
+885
| +6% | +$172K | ﹤0.01% | 2652 |
|
|
2021
Q1 | $2.08M | Sell |
15,726
-4,767
| -23% | -$754K | ﹤0.01% | 2845 |
|
|
2020
Q4 | $3.55M | Buy |
20,493
+10,879
| +113% | +$1.49M | ﹤0.01% | 2488 |
|
|
2020
Q3 | $1.07M | Sell |
9,614
-82,385
| -90% | -$6.59M | ﹤0.01% | 2940 |
|
|
2020
Q2 | $5.46M | Buy |
91,999
+65,888
| +252% | +$4.33M | ﹤0.01% | 2008 |
|
|
2020
Q1 | $1.76M | Sell |
26,111
-6,760
| -21% | -$534K | ﹤0.01% | 2544 |
|
|
2019
Q4 | $2.77M | Sell |
32,871
-1,607
| -5% | -$130K | ﹤0.01% | 2568 |
|
|
2019
Q3 | $2.58M | Sell |
34,478
-24,133
| -41% | -$1.93M | ﹤0.01% | 2581 |
|
|
2019
Q2 | $3.71M | Buy |
+58,611
| New | +$2.97M | ﹤0.01% | 2419 |
|
|
2018
Q4 | – | Sell |
-76,310
| Closed | -$4.01M | – | 3735 |
|
|
2018
Q3 | $4.01M | Sell |
76,310
-17,883
| -19% | -$712K | ﹤0.01% | 2481 |
|
|
2018
Q2 | $2.95M | Buy |
94,193
+46,810
| +99% | +$1.3M | ﹤0.01% | 2560 |
|
|
2018
Q1 | $1.03M | Sell |
47,383
-25,187
| -35% | -$542K | ﹤0.01% | 2961 |
|
|
2017
Q4 | $1.47M | Buy |
72,570
+13,960
| +24% | +$269K | ﹤0.01% | 2813 |
|
|
2017
Q3 | $1.16M | Buy |
+58,610
| New | +$1.15M | ﹤0.01% | 2895 |
|
Other funds holding NVCR
SCM
Ameriprise's NVCR Position: Q2 2025 in Review
Ameriprise sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 22,118 shares — an estimated $394K sold.
Ameriprise first reported a position in NVCR in Q3 2017 and held it in 28 quarters. The position peaked at $6.41M in Q4 2021. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.
- Ameriprise reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
- Ameriprise sold 22,118 NovoCure shares in Q2 2025, an estimated $394K.
- Ameriprise first reported a position in NovoCure in Q3 2017 and held it in 28 quarters.
- Ameriprise's NovoCure position peaked at $6.41M in Q4 2021.
- 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.
Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.